Evaluating Efficacy of Antiseptic Mouth Rinses on Salivary SARS-CoV-2 Infectivity

评估抗菌漱口水对唾液 SARS-CoV-2 感染性的功效

• 批准号: 10589946
• 负责人: Laura Anne Jacox
• 金额: $ 15.55万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-03-10 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10589946
• 关键词: 2019-nCoV; Address; Adoption; Aerosols; Antibodies; Antibody Response; Antibody titer measurement; Antigenic Specificity; Biological Assay; COVID-19; COVID-19 pandemic; COVID-19 patient; Caring; Cessation of life; Cetylpyridinium Chloride; Chlorhexidine; Clinical Trials; Collaborations; Critical Illness; Data; Dental; Dentists; Development; Discipline; Disease; Ensure; Ethanol; Evaluation; FDA approved; Face; Faculty; Frontline worker; Goals; Head; Head and neck structure; Health Personnel; Healthcare; Hydrogen Peroxide; Immune response; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Immunologics; In Vitro; Infection; Inflammation; Inflammatory Response; Intervention; Investigation; Knowledge; Local Anti-Infective Agents; Maps; Measures; Mediator; Methodology; Mouthwash; Neck; Occupational Exposure; Oral; Oral Characters; Oral cavity; Outcome; Outpatients; Patients; Population; Povidone-Iodine; Prognostic Marker; Property; Proteins; Protocols documentation; Public Health; Qualifying; Randomized, Controlled Trials; Reporting; Reverse Transcriptase Polymerase Chain Reaction; SARS-CoV-2 infection; Saliva; Salivary; Salivary Glands; Sampling; School Dentistry; Site; Social Environment; Technology; Time; Ultrasonics; Vaccines; Viral; Viral Load result; Virus; Virus Replication; Work; Workplace; anti-viral efficacy; biobank; chemokine; cohort; cytokine; diagnostic biomarker; economic impact; efficacy evaluation; experience; health care settings; high risk; in vivo; infection risk; innovation; novel; novel diagnostics; pathogen; professional atmosphere; public health emergency; randomized, clinical trials; respiratory; saliva sample; social; socioeconomics; therapeutic biomarker; tool; translational impact; transmission process; viral transmission

ABSTRACT Evaluating the antiviral potential of widely available commercial antiseptic rinses on SARS-CoV-2 infectivity holds great potential for rapidly reducing viral transmission, particularly as novel strains emerge. Given that SARS- CoV-2 is transmitted primarily through aerosols and salivary and respiratory secretions, strategies to reduce viral burden is an attractive approach to mitigating spread; this is particularly true for dental and other healthcare settings which have high patient volumes, require work in close proximity to the head and neck, and generate procedural aerosols. Though studies have demonstrated that some antiseptic mouth rinses have antiviral properties against SARS-CoV-2 in vitro and other enveloped viruses in vivo, data are still emerging from recent randomized clinical trials (RCT), including ours at the Adams School of Dentistry, regarding whether antiseptic mouth rinses reduce SARS-CoV-2 in vivo. To address this gap in knowledge, we propose to determine whether mouth rinses containing ethanol, hydrogen peroxide, povidone-iodine, chlorhexidine, or cetylpyridinium chloride reduce SARS-CoV-2 viral load, replication and infectivity (Aim 1) and to characterize salivary inflammatory and antibody responses associated with early SARS-CoV-2 infection (Aim 2) using salivary samples derived from our recent COVID-19+ patient RCT. Altogether, the data generated from these aims will demonstrate whether antiseptic rinses reduce salivary SARS-CoV-2 viral load and infectivity, and will characterize the local inflammatory response to SARS-CoV-2 in the oral cavity with the ultimate goal of limiting viral spread. These studies will generate data to develop feasible, inexpensive, rapidly implementable protocols to mitigate the spread of SARS-CoV-2 and address this urgent public health need with broad translational impact. Our interdisciplinary team is uniquely qualified to conduct the proposed work as we have the innovative methodologies, BLS2+ facilities, SARS-CoV-2+ samples, and expertise to achieve our aims. This application includes collaboration between experienced and junior faculty across multiple disciplines to ensure the rigor and translatability of our findings.

摘要 评价广泛使用的市售抗菌冲洗液对SARS-CoV-2感染性的抗病毒潜力 快速减少病毒传播的巨大潜力，特别是当新菌株出现时。鉴于SARS- CoV-2主要通过气溶胶、唾液和呼吸道分泌物传播， 负担是一个有吸引力的方法，以减轻传播;这是特别真实的牙科和其他医疗保健 具有高患者量的设置，需要在头部和颈部附近工作，并产生 程序性气溶胶。尽管研究表明，一些抗菌漱口水具有抗病毒作用， 针对SARS-CoV-2在体外和其他包膜病毒在体内的特性，数据仍然出现从最近的 随机临床试验（RCT），包括我们在亚当斯牙科学院，关于是否防腐 漱口水在体内减少SARS-CoV-2。为了弥补这一知识差距，我们建议确定是否 含乙醇、过氧化氢、聚维酮碘、氯己定或西吡氯铵的漱口液 降低SARS-CoV-2病毒载量、复制和感染性（目标1），并表征唾液炎性和 与早期SARS-CoV-2感染相关的抗体应答（Aim 2），使用来自 我们最近的COVID-19+患者RCT。总之，这些目标产生的数据将表明， 抗菌漱口水可降低唾液SARS-CoV-2病毒载量和感染性， 口腔中对SARS-CoV-2的炎症反应，最终目的是限制病毒传播。这些 研究将产生数据，以制定可行的，廉价的，可迅速实施的协议，以减轻 SARS-CoV-2的传播，并解决这一具有广泛转化影响的紧迫公共卫生需求。我们 跨学科团队是唯一有资格进行拟议的工作，因为我们有创新的 方法，BLS 2+设施，SARS-CoV-2+样本和专业知识，以实现我们的目标。本申请 包括跨多个学科的经验丰富的和初级教师之间的合作，以确保严谨性， 翻译我们的发现。